Interleukin-6 gene therapy
Latest Information Update: 06 Dec 2007
At a glance
- Originator Yeda
- Class Cytokine genes; Gene therapies; Interleukins
- Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer